Anaemia and pathologic complete response rate according to carboplatin dose in <scp>HER2</scp> + breast cancer treated with neoadjuvant <scp>TCHP</scp>-Reference-Cited by-同舟云学术

Anaemia and pathologic complete response rate according to carboplatin dose in HER2 + breast cancer treated with neoadjuvant TCHP

Published:2022-07-15 Issue:2 Volume:12 Page:1409-1417
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Ji Jung Hwan¹²,Bae Soong June¹²^ORCID,Kim Seul‐Gi³^ORCID,Kim Min Hwan³,Kim Gun‐Min³,Sohn Joohyuk³,Jeong Joon¹²,Kim Jee Hung²⁴^ORCID,Ahn Sung Gwe¹²^ORCID

Affiliation:

1. Department of Surgery, Gangnam Severance Hospital Yonsei University College of Medicine Seoul Republic of Korea

2. Institute for Breast Cancer Precision Medicine Yonsei University College of Medicine Seoul Republic of Korea

3. Division of Medical Oncology, Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea

4. Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital Yonsei University College of Medicine Seoul Republic of Korea

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5022

Reference38 articles.

1. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

2. Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

3. Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China;World Journal of Surgical Oncology;2024-08-21

2. Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade;Cancers;2024-02-19